Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline
Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology.
In parallel, Exscientia is building a new 26,000 square foot robotic laboratory at nearby Milton Park, Oxfordshire focused on the automation of chemistry and biology to accelerate drug discovery. This will take Exscientia towards its goal of drugs designed AI, made by robot.
“Exscientia has grown significantly in 2021, driven by new partnerships with leading pharma and biotech companies, as well as by our in-house drug discovery work. Our pipeline includes more than 25 active research programs across therapeutic areas, with a focus on immunology and oncology,” said Dr. David Hallet, Chief Operating Officer of Exscientia. “To meet this expanded growth, we have added more than 100 employees to-date in 2021 and are excited to continue this growth as we seek to add more world-class scientists and technologists to our team.”
Exscientia is a global company, headquartered in Oxford, UK with sites in Miami (FL, US), Vienna (Austria), Dundee (Scotland, UK) and Osaka (Japan). The company currently has over 170 people, roughly split between technologists and drug discovery scientists, with a united goal to find smarter and faster ways to discover and develop new drugs.
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CELLTRION-HEALTHCARE18.9.2021 15:36:17 CEST | Press release
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
IPSEN18.9.2021 06:32:11 CEST | Press release
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
IN-UNIFRAX17.9.2021 20:48:10 CEST | Press release
Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line
THE-EARTHSHOT-PRIZE17.9.2021 19:03:10 CEST | Press release
Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize
NY-WIPRO-LIMITED17.9.2021 15:34:05 CEST | Press release
Wipro Announces Co-innovation Space with Google Cloud
CA-ZYNGA17.9.2021 15:02:11 CEST | Press release
Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat
MA-BEIGENE17.9.2021 14:02:08 CEST | Press release
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom